Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

British Medical Journal

Volumn 325, Issue 7365, 2002, Pages 624-627

  Mamdani, Muhammad ^a   Rochon, Paula A ^b   Juurlink, David N ^c   Kopp, Alex ^a   Anderson, Geoffrey M ^d   Naglie, Gary ^e   Austin, Peter C ^a   Laupacis, Andreas ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; ARTHROTEC; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

ADULT; AGED; AGING; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2; DICLOFENAC; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MISOPROSTOL; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 0037151906     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Misoprostol for co-prescription with NSAIDs. Drug Ther Bull 1990;28:25-6.
2. Barat I, Andreasen F, Damsgaard EMS. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000;56:501-9.
3. Sayer GP, Britt H, Horn F, Bhasale A, McGeechan K, Charles J, et al. Measures of health and health care delivery in general practice in Australia. Australian Institute of Health and Welfare. April 2000. (www.aihw.gov.au/publications/health/mhhcdgpa/index.html (accessed 27 May 2002))
4. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
5. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000;132:134-43.
6. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
7. Aalykke C, Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001;15:705-22.
8. Hernandez-Diaz S, Rodriguez LAG. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002;55:157-63.
9. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
10. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
11. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.